Phase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEK

Oncology

MIDD

Trial design and analysis

Pharmacometrics

ACoP 15 (Nov 2024), Poster: W-019

Yamamura A, Axel A, King P, Funt J, Foley EM, Kovar C, Bergstrand M, Mezzalana E, Chenel M, Hayreh V, Hall B